Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
HSTC HST Global	$0.83	$0.77	$0.23 ▼ $1.11	$47.95M	-1.19	1,185 shs	N/A
HUMA Humacyte	$1.87 +8.1%	$1.86	$1.15 ▼ $9.97	$290.07M	1.64	3.71 million shs	8.56 million shs
IVA Inventiva	$3.50 -2.2%	$3.26	$1.53 ▼ $4.05	$183.67M	0.8	62,919 shs	1,693 shs
MDWD MediWound	$19.43 -2.5%	$17.15	$12.78 ▼ $24.00	$210.00M	0.3	90,227 shs	85,188 shs

The Best High-Yield Dividend Stocks for 2025

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
HSTC HST Global	0.00%	0.00%	0.00%	+13.70%	-24.55%
HUMA Humacyte	+8.09%	+53.28%	+25.50%	-52.30%	-70.87%
IVA Inventiva	-2.23%	-2.78%	+6.38%	+41.13%	-4.11%
MDWD MediWound	-2.46%	+8.79%	+17.12%	+4.35%	+9.16%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
HSTC HST Global	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
HUMA Humacyte	2.7395 of 5 stars	3.5	2.0	0.0	0.0	2.5	3.3	0.6
IVA Inventiva	2.2203 of 5 stars	3.4	2.0	0.0	0.0	2.7	1.7	0.6
MDWD MediWound	1.6087 of 5 stars	3.5	1.0	0.0	0.0	2.1	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
HSTC HST Global	0.00	N/A	N/A	N/A
HUMA Humacyte	3.00	Buy	$11.71	526.43% Upside
IVA Inventiva	2.80	Moderate Buy	$10.40	197.14% Upside
MDWD MediWound	3.00	Buy	$29.75	53.11% Upside

Current Analyst Ratings Breakdown

Latest HSTC, MDWD, HUMA, and IVA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/14/2025	HUMA Humacyte	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$4.00
5/14/2025	HUMA Humacyte	Benchmark Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$17.00 ➝ $14.00
5/13/2025	HUMA Humacyte	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00 ➝ $25.00
5/2/2025	MDWD MediWound	Alliance Global Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$25.00
4/4/2025	IVA Inventiva	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$12.00 ➝ $9.00
3/28/2025	IVA Inventiva	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$13.00 ➝ $13.00
3/26/2025	HUMA Humacyte	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00 ➝ $25.00
3/20/2025	MDWD MediWound	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00 ➝ $25.00
3/12/2025	HUMA Humacyte	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00 ➝ $15.00
3/7/2025	HUMA Humacyte	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00 ➝ $25.00
2/28/2025	MDWD MediWound	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$39.00

(Data available from 5/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
HSTC HST Global	N/A	N/A	N/A	N/A	N/A	N/A
HUMA Humacyte	$1.57M	184.76	N/A	N/A	$0.13 per share	14.38
IVA Inventiva	$9.20M	19.97	N/A	N/A	($0.67) per share	-5.22
MDWD MediWound	$20.22M	10.38	N/A	N/A	$3.43 per share	5.66

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
HSTC HST Global	-$150K	-$0.02	N/A	∞	N/A	N/A	-13,072.91%	-31.66%	N/A
HUMA Humacyte	-$110.78M	-$1.26	N/A	N/A	N/A	N/A	-942.81%	-93.82%	N/A
IVA Inventiva	-$119.51M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A
MDWD MediWound	-$6.72M	-$3.07	N/A	N/A	N/A	-142.29%	-82.17%	-33.67%	5/21/2025 (Estimated)

Latest HSTC, MDWD, HUMA, and IVA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/21/2025	Q1 2025	MDWD MediWound	-$0.65	N/A	N/A	N/A	$5.20 million	N/A
5/13/2025	Q1 2025	HUMA Humacyte	-$0.19	-$0.10	+$0.09	$0.28	$0.46 million	$0.52 million
3/28/2025	Q4 2024	HUMA Humacyte	-$0.23	-$0.16	+$0.07	-$0.16	$0.64 million	$7.23 million
3/19/2025	Q4 2024	MDWD MediWound	-$0.59	-$0.36	+$0.23	-$0.36	$5.79 million	$5.84 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
HSTC HST Global	N/A	N/A	N/A	N/A	N/A
HUMA Humacyte	N/A	N/A	N/A	N/A	N/A
IVA Inventiva	N/A	N/A	N/A	N/A	N/A
MDWD MediWound	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
HSTC HST Global	N/A	0.25	0.25
HUMA Humacyte	N/A	1.10	1.10
IVA Inventiva	N/A	0.59	0.59
MDWD MediWound	N/A	2.11	1.99

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
HSTC HST Global	N/A
HUMA Humacyte	44.71%
IVA Inventiva	19.06%
MDWD MediWound	46.83%

Insider Ownership

Company	Insider Ownership
HSTC HST Global	65.82%
HUMA Humacyte	11.20%
IVA Inventiva	32.00%
MDWD MediWound	9.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
HSTC HST Global	1	57.77 million	16.33 million	Not Optionable
HUMA Humacyte	150	155.12 million	111.76 million	Optionable
IVA Inventiva	100	52.48 million	35.68 million	Not Optionable
MDWD MediWound	80	10.81 million	9.79 million	Optionable

HSTC, MDWD, HUMA, and IVA Headlines

Recent News About These Companies

MediWound (MDWD) Projected to Post Quarterly Earnings on Wednesday

May 14 at 2:58 AM | americanbankingnews.com

MediWound Announces Publication of Phase II EscharEx® Data Demonstrating Superiority Over Collagenase in Venous Leg Ulcers

May 13 at 7:30 AM | globenewswire.com

MediWound Ltd. (NASDAQ:MDWD) Shares Sold by Renaissance Technologies LLC

May 9, 2025 | marketbeat.com

MediWound to Report First Quarter 2025 Financial Results

May 5, 2025 | globenewswire.com

MediWound (NASDAQ:MDWD) Earns Buy Rating from Analysts at Alliance Global Partners

May 4, 2025 | marketbeat.com

MediWound to Present New EscharEx® Data at Leading Wound Care Conferences

April 28, 2025 | globenewswire.com

MediWound (NASDAQ:MDWD) Stock Price Passes Above 50 Day Moving Average - Here's Why

April 27, 2025 | marketbeat.com

MediWound (NASDAQ:MDWD) Shares Cross Below 200-Day Moving Average - Time to Sell?

April 19, 2025 | marketbeat.com

Those who invested in MediWound (NASDAQ:MDWD) five years ago are up 30%

April 17, 2025 | finance.yahoo.com

MediWound reports Q4 EPS (36c), consensus (61c)

March 20, 2025 | markets.businessinsider.com

MediWound files $125M mixed securities shelf

March 20, 2025 | markets.businessinsider.com

Loss-Making MediWound Ltd. (NASDAQ:MDWD) Expected To Breakeven In The Medium-Term

March 20, 2025 | finance.yahoo.com

MediWound Ltd. (MDWD) Q4 2024 Earnings Call Transcript

March 20, 2025 | seekingalpha.com

MediWound Reports 2024 Financials and Strategic Advances

March 19, 2025 | tipranks.com

MediWound shares rise as Q4 loss is narrower than expected

March 19, 2025 | investing.com

MediWound (MDWD) Reports Q4 Loss, Tops Revenue Estimates

March 19, 2025 | zacks.com

MediWound Reports 2024 Financial Results and Strategic Advances

March 19, 2025 | tipranks.com

MediWound Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

March 19, 2025 | globenewswire.com

MediWound Q4 2024 Earnings Preview

March 18, 2025 | msn.com

Mediwound (MDWD) Receives a New Rating from Craig-Hallum

March 17, 2025 | markets.businessinsider.com

MediWound to Report Fourth Quarter and Full Year 2024 Financial Results

March 3, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?
By Jeffrey Neal Johnson | April 25, 2025
View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?
Why D-Wave's Project With Davidson Is a Game-Changer For Quantum
By Nathan Reiff | April 30, 2025
View Why D-Wave's Project With Davidson Is a Game-Changer For Quantum
Gold Rally Continues: These 3 Mining Stocks Are Likely to Benefit
By Chris Markoch | April 16, 2025
View Gold Rally Continues: These 3 Mining Stocks Are Likely to Benefit
AMD’s AI-Powered Stock Price Rally Just Shifted Gears
By Thomas Hughes | May 14, 2025
View AMD’s AI-Powered Stock Price Rally Just Shifted Gears
2 Healthcare Recession-Resistant Stocks Unaffected by Tariffs
By Jea Yu | April 15, 2025
View 2 Healthcare Recession-Resistant Stocks Unaffected by Tariffs

HSTC, MDWD, HUMA, and IVA Company Descriptions

HST Global OTCMKTS:HSTC

$0.83 0.00 (0.00%)

As of 05/13/2025

HST Global, Inc., operates as an integrated health and wellness biotechnology company in the United States. The company develops and/or acquires a network of wellness centers for the homeopathic and alternative treatment of late stage cancer and other life threatening diseases. It also focuses on the homeopathic and alternative product candidates that are undergoing or have already completed clinical testing for the treatment of late stage cancer and or/ life threatening diseases. HST Global, Inc. is headquartered in Hampton, Virginia.

Humacyte NASDAQ:HUMA

$1.87 +0.14 (+8.09%)

As of 05/14/2025 04:00 PM Eastern

Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.

Inventiva NASDAQ:IVA

$3.50 -0.08 (-2.23%)

As of 05/14/2025 03:54 PM Eastern

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company was founded in 2011 and is headquartered in Daix, France.

MediWound NASDAQ:MDWD

$19.43 -0.49 (-2.46%)

As of 05/14/2025 04:00 PM Eastern

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; and MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time